Virus inoculation and treatment regimens for evaluating anti-filovirus monoclonal antibody efficacy in vivo.

ABSTRACT: The development of monoclonal antibodies to treat disease caused by filoviruses, particularly Ebola virus, has risen steeply in recent years thanks to several key studies demonstrating their remarkable therapeutic potential. The increased drive to develop new and better monoclonal antibodies has necessarily seen an increase in animal model efficacy testing, which is critical to the pre-clinical development of any novel countermeasure. Primary and secondary efficacy testing against filoviruses typically makes use of one or more rodent models (mice, guinea pigs, and occasionally hamsters) or the more recently described ferret model, although the exact choice of model depends on the specific filovirus being evaluated. Indeed, no single small animal model exists for all filoviruses, and the us

SUBMITTER: Banadyga L 

PROVIDER: S-EPMC7347303 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature